<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03665207</url>
  </required_header>
  <id_info>
    <org_study_id>S61145</org_study_id>
    <secondary_id>2018-000756-17</secondary_id>
    <nct_id>NCT03665207</nct_id>
  </id_info>
  <brief_title>Tight Versus Liberal Blood Glucose Control in Adult Critically Ill Patients</brief_title>
  <acronym>TGC-fast</acronym>
  <official_title>Impact of Tight Blood Glucose Control Within Normal Fasting Ranges With Insulin Titration Prescribed by the Leuven Algorithm in Adult Critically Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Research Foundation Flanders</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>KU Leuven</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Critically ill patients usually develop hyperglycemia, which is associated with an increased
      risk of morbidity and mortality. Controversy exists on whether targeting normal blood glucose
      concentrations with insulin therapy, referred to as tight blood glucose control (TGC)
      improves outcome of these patients, as compared to tolerating hyperglycemia. It remains
      unknown whether TGC, when applied with optimal tools to avoid hypoglycemia, is beneficial in
      a context of withholding early parenteral nutrition. The TGC-fast study hypothesizes that TGC
      is beneficial in adult critically ill patients not receiving early parenteral nutrition, as
      compared to tolerating hyperglycemia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2018</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of ICU dependency</measure>
    <time_frame>up to 1 year after randomization</time_frame>
    <description>crude number of days with need for vital organ support and time to live discharge from ICU</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU Mortality</measure>
    <time_frame>up to 1 year after randomization (with and without censoring at 90 days post randomization)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Mortality</measure>
    <time_frame>up to 1 year after randomization (with and without censoring at 90 days post randomization)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day mortality</measure>
    <time_frame>up to 90 days post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose concentrations in ICU</measure>
    <time_frame>up to 1 year post randomization, with and without censoring at 90 days post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU dependency</measure>
    <time_frame>up to 90 days post randomization</time_frame>
    <description>crude number of days with need for vital organ support and time to live discharge from ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in hospital</measure>
    <time_frame>up to 1 year post randomization, with and without censoring at 90 days post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to (live) discharge from hospital</measure>
    <time_frame>up to 1 year post randomization, with and without censoring at 90 days post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new infections in ICU</measure>
    <time_frame>up to 1 year post randomization, with and without censoring at 90 days post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of new infections in ICU</measure>
    <time_frame>up to 1 year post randomization, with and without censoring at 90 days post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of antibiotic treatment in ICU</measure>
    <time_frame>up to 1 year post randomization, with and without censoring at 90 days post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of daily C-reactive protein in ICU</measure>
    <time_frame>up to 1 year post randomization, with and without censoring at 90 days post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to final (live) weaning from mechanical respiratory support in ICU</measure>
    <time_frame>up to 1 year post randomization, with and without censoring at 90 days post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with need for a tracheostomy during ICU stay</measure>
    <time_frame>up to 1 year post randomization, with and without censoring at 90 days post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of clinical, electrophysiological and morphological signs of respiratory and peripheral muscle weakness in ICU</measure>
    <time_frame>up to 1 year post randomization, with and without censoring at 90 days post randomization (in selected centers)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute kidney injury in ICU</measure>
    <time_frame>up to 1 year post randomization, with and without censoring at 90 days post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of acute kidney injury</measure>
    <time_frame>up to 1 year post randomization, with and without censoring at 90 days post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of recovery from acute kidney injury</measure>
    <time_frame>up to 1 year post randomization, with and without censoring at 90 days post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with need for new renal replacement therapy in ICU</measure>
    <time_frame>up to 1 year post randomization, with and without censoring at 90 days post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of recovery from new renal replacement therapy</measure>
    <time_frame>up to 1 year post randomization, with and without censoring at 90 days post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with need for hemodynamic support in ICU</measure>
    <time_frame>up to 1 year post randomization, with and without censoring at 90 days post randomization</time_frame>
    <description>Hemodynamic support is defined as the need for either pharmacological (inotropes/vasopressors) and/or mechanical hemodynamic support.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hemodynamic support in ICU</measure>
    <time_frame>up to 1 year post randomization, with and without censoring at 90 days post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to (live) weaning from hemodynamic support</measure>
    <time_frame>up to 1 year post randomization, with and without censoring at 90 days post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of markers of liver dysfunction in ICU</measure>
    <time_frame>up to 1 year post randomization, with and without censoring at 90 days post randomization</time_frame>
    <description>including transaminases, gamma-glutamyltransferase, alkaline phosphatase and bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of readmissions to the ICU within 48 hours after discharge</measure>
    <time_frame>up to 1 year post randomization, with and without censoring at 90 days post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of delirium in ICU (in selected centers)</measure>
    <time_frame>up to 1 year post randomization, with and without censoring at 90 days post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehabilitation/functional outcome</measure>
    <time_frame>up to 2 years post randomization</time_frame>
    <description>including the score obtained from the 36-item short form health survey (SF-36). The score ranges from 0 to 100, with 100 being the best possible outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehabilitation/functional outcome in patients with brain injury</measure>
    <time_frame>up to 1 year post randomization</time_frame>
    <description>including the score obtained on the modified Rankin scale. The score ranges from 0 to 6, with 0 being the best possible outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehabilitation/functional outcome in patients with brain injury</measure>
    <time_frame>up to 1 year post randomization</time_frame>
    <description>including the score obtained on the extended Glasgow outcome scale. The score ranges from 1 to 8, with 8 being the best possible outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lipid concentrations in ICU</measure>
    <time_frame>up to 4 years post randomization (in selected centers)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength</measure>
    <time_frame>up to 4 years post randomization (in selected centers)</time_frame>
    <description>including handgrip strength as % of the predicted value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehabilitation/Functional outcome</measure>
    <time_frame>up to 4 years post randomization (in selected centers)</time_frame>
    <description>including the 6-minutes walking distance in meter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehabilitation/Functional outcome</measure>
    <time_frame>up to 4 years post randomization (in selected centers)</time_frame>
    <description>including the score obtained from the SF-36 health survey. The score ranges from 0 to 100, with 100 being the best possible outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of recovery of organ function</measure>
    <time_frame>up to 4 years post randomization (in selected centers)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>up to 4 years post randomization (in selected centers)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of intensive care resources during index hospitalization</measure>
    <time_frame>up to 1 year post randomization</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Biochemical markers on blood samples</measure>
    <time_frame>up to 4 years post randomization</time_frame>
    <description>including amino acid levels, blood lipid levels, cytokines, hypothalamic-pituitary hormones, glucagon, C-peptide, (epi)genetic markers</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of patients with muscle degeneration during ICU stay</measure>
    <time_frame>up to 30 days post randomization (in selected centers)</time_frame>
    <description>assessed by microscopy</description>
  </other_outcome>
  <other_outcome>
    <measure>Biochemical markers in muscle tissue during ICU stay</measure>
    <time_frame>up to 30 days post randomization (in selected centers)</time_frame>
    <description>including tissular glucose and metabolites, lipid metabolites, myofibrillary proteins, mitochondrial complex activity, autophagy markers, proteasome activity, (epi)genetic markers</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of patients with pathological cellular alterations in fat tissue during ICU stay</measure>
    <time_frame>up to 30 days post randomization (in selected centers)</time_frame>
    <description>assessed by microscopy</description>
  </other_outcome>
  <other_outcome>
    <measure>Biochemical markers in fat tissue during ICU stay</measure>
    <time_frame>up to 30 days post randomization (in selected centers)</time_frame>
    <description>including tissular glucose and metabolites, lipid metabolites, mitochondrial complex activity, autophagy markers, (epi)genetic markers</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of patients with muscle degeneration</measure>
    <time_frame>up to 4 years post randomization (in selected centers)</time_frame>
    <description>assessed by microscopy</description>
  </other_outcome>
  <other_outcome>
    <measure>Biochemical markers in muscle tissue</measure>
    <time_frame>up to 4 years post randomization (in selected centers)</time_frame>
    <description>including tissular glucose and metabolites, lipid metabolites, myofibrillary proteins, mitochondrial complex activity, autophagy markers, proteasome activity, (epi)genetic markers</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of patients with pathological cellular alterations in fat tissue</measure>
    <time_frame>up to 4 years post randomization (in selected centers)</time_frame>
    <description>assessed by microscopy</description>
  </other_outcome>
  <other_outcome>
    <measure>Biochemical markers in fat tissue</measure>
    <time_frame>up to 4 years post randomization (in selected centers)</time_frame>
    <description>including tissular glucose and metabolites, lipid metabolites, mitochondrial complex activity, autophagy markers, (epi)genetic markers</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">9230</enrollment>
  <condition>Critical Illness</condition>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>Tight glucose control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Target normal fasting blood glucose concentrations (80-110 mg/dl) with insulin therapy, administered through continuous intravenous infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liberal glucose control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tolerate hyperglycemia up to 215 mg/dl. In patients requiring insulin therapy, insulin will be titrated to target blood glucose concentrations between 180 and 215 mg/dl.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>When blood glucose exceeds the preset target, insulin will be administered through continuous intravenous infusion. Insulin will be titrated according to frequent measurement of blood glucose and with use of the LOGIC-insulin algorithm in the experimental group. The intervention will be stopped upon ICU discharge, or until the patient is able to resume oral feeding, or until the patient no longer has a central venous catheter, whatever comes first.</description>
    <arm_group_label>Liberal glucose control</arm_group_label>
    <arm_group_label>Tight glucose control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Adult patient (18 years or older) admitted to a participating intensive care unit (ICU)

        Exclusion Criteria:

          -  Patients with a do not resuscitate (DNR) order at the time of ICU admission

          -  Patients expected to die within 12 hours after ICU admission (= moribund patients)

          -  Patients able to receive oral feeding (not critically ill)

          -  Patients without arterial and without central venous line and without imminent need to
             place it as part of ICU management (not critically ill)

          -  Patients previously included in the trial (when readmission is within 48 hours post
             ICU discharge, the trial intervention will be resumed)

          -  Patients already enrolled in another randomized controlled trial (RCT) powered for
             clinical endpoints

          -  Patients transferred from a non-participating ICU with a pre-admission ICU stay &gt;7
             days

          -  Patients planned to receive parenteral nutrition during the first week in ICU

          -  Patients suffering from diabetic ketoacidotic or hyperosmolar coma on ICU admission

          -  Patients with inborn metabolic diseases

          -  Patients with insulinoma

          -  Patients known to be pregnant or lactating

          -  Informed consent refusal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Greet Van den Berghe, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>KU Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Gunst, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KU Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Greet Van den Berghe, MD, PhD</last_name>
    <phone>+32 16 344021</phone>
    <email>greet.vandenberghe@kuleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jan Gunst, MD, PhD</last_name>
    <phone>+32 16 344021</phone>
    <email>jan.gunst@kuleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Intensive Care Medicine, University Hospital Antwerp</name>
      <address>
        <city>Antwerp</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe Jorens, MD, PhD</last_name>
      <phone>+32 3 8213635</phone>
      <email>Philippe.Jorens@uza.be</email>
    </contact>
    <investigator>
      <last_name>Philippe Jorens, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Intensive Care Medicine, University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique Benoit, MD, PhD</last_name>
      <phone>+32 9 3322775</phone>
      <email>Dominique.Benoit@UGent.be</email>
    </contact>
    <investigator>
      <last_name>Dominique Benoit, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Hoste, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Harlinde Peperstraete, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joris Vermassen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Intensive Care Medicine, Jessa Hospital Hasselt</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jasperina Dubois, MD</last_name>
      <phone>+ 32 11 308971</phone>
      <email>jasperina.dubois@jessazh.be</email>
    </contact>
    <investigator>
      <last_name>Jasperina Dubois, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Intensive Care Medicine, University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Greet Van den Berghe, MD, PhD</last_name>
      <phone>+32 16 344021</phone>
      <email>greet.vandenberghe@kuleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Jan Gunst, MD, PhD</last_name>
      <phone>+32 16 344021</phone>
      <email>jan.gunst@kuleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Greet Van den Berghe, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan Gunst, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Care Unit, University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Greet Hermans, MD, PhD</last_name>
      <phone>+32 16 344275</phone>
      <email>greet.hermans@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Greet Hermans, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Wilmer, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001 Nov 8;345(19):1359-67.</citation>
    <PMID>11794168</PMID>
  </reference>
  <reference>
    <citation>Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, Van Wijngaerden E, Bobbaers H, Bouillon R. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006 Feb 2;354(5):449-61.</citation>
    <PMID>16452557</PMID>
  </reference>
  <reference>
    <citation>Vlasselaers D, Milants I, Desmet L, Wouters PJ, Vanhorebeek I, van den Heuvel I, Mesotten D, Casaer MP, Meyfroidt G, Ingels C, Muller J, Van Cromphaut S, Schetz M, Van den Berghe G. Intensive insulin therapy for patients in paediatric intensive care: a prospective, randomised controlled study. Lancet. 2009 Feb 14;373(9663):547-56. doi: 10.1016/S0140-6736(09)60044-1. Epub 2009 Jan 26.</citation>
    <PMID>19176240</PMID>
  </reference>
  <reference>
    <citation>NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, HÃ©bert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009 Mar 26;360(13):1283-97. doi: 10.1056/NEJMoa0810625. Epub 2009 Mar 24.</citation>
    <PMID>19318384</PMID>
  </reference>
  <reference>
    <citation>Casaer MP, Mesotten D, Hermans G, Wouters PJ, Schetz M, Meyfroidt G, Van Cromphaut S, Ingels C, Meersseman P, Muller J, Vlasselaers D, Debaveye Y, Desmet L, Dubois J, Van Assche A, Vanderheyden S, Wilmer A, Van den Berghe G. Early versus late parenteral nutrition in critically ill adults. N Engl J Med. 2011 Aug 11;365(6):506-17. doi: 10.1056/NEJMoa1102662. Epub 2011 Jun 29.</citation>
    <PMID>21714640</PMID>
  </reference>
  <reference>
    <citation>Fivez T, Kerklaan D, Mesotten D, Verbruggen S, Wouters PJ, Vanhorebeek I, Debaveye Y, Vlasselaers D, Desmet L, Casaer MP, Garcia Guerra G, Hanot J, Joffe A, Tibboel D, Joosten K, Van den Berghe G. Early versus Late Parenteral Nutrition in Critically Ill Children. N Engl J Med. 2016 Mar 24;374(12):1111-22. doi: 10.1056/NEJMoa1514762. Epub 2016 Mar 15.</citation>
    <PMID>26975590</PMID>
  </reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>August 29, 2018</study_first_submitted>
  <study_first_submitted_qc>September 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2018</study_first_posted>
  <last_update_submitted>September 28, 2018</last_update_submitted>
  <last_update_submitted_qc>September 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>KU Leuven</investigator_affiliation>
    <investigator_full_name>Greet Van den Berghe</investigator_full_name>
    <investigator_title>Full professor, Head of the clinical department and laboratory of intensive care medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data sharing will be considered only on a collaborative basis with PIs, after evaluation of the proposed study protocol and statistical analysis plan.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

